Plain-English translation of NCT05868525 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a lower dose of aspirin (81 mg) works just as well as a higher dose (325 mg) at preventing stroke in people who have suffered a blunt injury to major blood vessels in the neck or head. Doctors currently use aspirin to reduce stroke risk in these patients, but researchers want to find out if the lower dose is equally effective and causes fewer bleeding problems.
After a blunt injury to neck or head blood vessels, patients are at risk for stroke. While this medication is commonly used to prevent that complication, doctors aren't sure if a lower dose might be safer (causing less bleeding) while still protecting patients just as well.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to take either 81 mg or 325 mg of aspirin by mouth once daily. The study will track whether you experience a stroke or any bleeding complications while on the medication. You will likely have follow-up visits and imaging to monitor your recovery and ensure the treatment is working safely.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States